Relyea Zuckerberg Hanson LLC Has $391,000 Stock Position in Danaher Co. (NYSE:DHR)

Relyea Zuckerberg Hanson LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 9.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,905 shares of the conglomerate’s stock after selling 205 shares during the quarter. Relyea Zuckerberg Hanson LLC’s holdings in Danaher were worth $391,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Danaher by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after purchasing an additional 315,912 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Danaher by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock worth $3,056,996,000 after purchasing an additional 315,446 shares in the last quarter. Norges Bank acquired a new stake in shares of Danaher during the 4th quarter worth about $2,130,740,000. Bank of New York Mellon Corp grew its holdings in Danaher by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after acquiring an additional 441,012 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Danaher by 14.3% during the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock worth $1,821,477,000 after acquiring an additional 992,594 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 2.2%

Danaher stock opened at $200.51 on Friday. The company’s 50 day simple moving average is $192.80 and its 200 day simple moving average is $211.19. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The firm has a market capitalization of $143.50 billion, a price-to-earnings ratio of 37.98, a PEG ratio of 2.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. As a group, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher’s payout ratio is 24.85%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Wolfe Research decreased their price objective on shares of Danaher from $275.00 to $220.00 and set an “outperform” rating on the stock in a report on Monday, April 7th. Robert W. Baird decreased their price objective on shares of Danaher from $231.00 to $225.00 and set an “outperform” rating on the stock in a report on Wednesday, April 23rd. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. UBS Group decreased their price objective on shares of Danaher from $275.00 to $240.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their price objective on shares of Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $248.17.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares of the company’s stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.